Loading in 2 Seconds...
Loading in 2 Seconds...
China Healthcare Market Overview and Coland Development Strategy. Coland Holdings Limited CEO Leo Lee 2014 . 3.6. Coland Development Strategy. 2. China Healthcare Market Overview. 1. In 2013, China's population exceeded 1.36 billion - 1/5 of world total
ColandHoldings LimitedCEOLeo Lee
(India-1.24 billion, U.S-320 million, Total 7 billion world Population)
China's GDP per capita is USD$6,824 - 7.1% annual growth
(Doubling GDP in 7 years - the fastest country in the world
2012 China’s total health expenditure to GDP reached 5.57%, 0.42% increase from prior year
(Brazil 8.8%, South Africa 9.2%, Russia 5.6%, India 4.2%)
In 2013 the total value of China's medical industry reached RMB 2.17 trillion
(Estimated in 2015 to reach 3 trillion, average annual growth rate of 18%)
2013 China's average life expectancy is 76 , the elderly population exceeded 200 million
(Expected in 2020 will reach 243 million/ in 2025 will exceed 300 million
Source: Southern Medical Economic Institute, "China Medicine Economic operation of the system."
Source: 2012 China Health Statistics Yearbook; National Food and Drug Administration;
national health and birth control committees People's Republic of China
Foreign manufacturers withdraw from Essential-drug market: The tender process at provincial level will phase out favorable treatment in foreign original drugs. As results of regulated lower price, foreign manufacturers will gradually to withdraw from low-end drug-market , domestic-produced medicine will accelerate import substitution.
The original drugs’ patent will be expired and price will be substantially reduced, and the price gap between domestic generic drugs to be reduced 30% or even lower in the next couple years.
In the near future, only first-released or genuine generic drugs or clinically differentiated medicines will benefit from differential pricing - the incentives offered by NDRC.
CFDA issued a series of new GMP regulations, requiring drug manufacturers to be certified and completed in registration prior to end of 2015.
The government introduced policies to support innovative local companies, by providing financial support for R&D businesses with independent IP rights, speeding up review process, encouraging the adoption of industry consolidation, which witnessed by large state-owned pharmaceutical companies to lead the integration and restructuring of China's pharmaceutical industry.
Source: 2012, Statistics China, People's Republic of China national health and
birth control committee; National Food and Drug Administration?
The city-level hospitals will account for 50% of total market growth in 2011-2020, which will remain as major battlefield for pharmaceutical companies
The county-level hospitals will become increasingly important. The government will continue to increases funding to finance new infrastructure, physician training, professional competence development in county hospitals; the government has also introduced types of insurance reimbursement policies to encourage “treatment in local hospitals“, wide-spreading local medical hospitals, such as community/rural health centers.
Source: China Medical Association, "2013 China Medical Devices Industry Development Blue Book"
China’s medical device market size has increased to 212 Billion in 2013, up from 17.9 Billion in 2001. By removing price factor, the increase has more than 10 times in the past 12 years.
Medical device as % of total healthcare market size: 42% Worldwide, <20% in China
Medical device cost per capita: U.S. $329 / person, China $13 / person
"Medical Devices Regulations" amended to adjust the product registration and licensing order to change production sites, will be converted to first register and then apply for license.
New GMP requires all Class III medical
device must meet requirements by 2015,
completed by end 2017
New GSP regulated
sales, after-sales service,
and other business sectors,
Innovative products with industry support efforts
Regulatory amendments to facilitate industrydevelopment
2012 China wearable
device Market size reached
610 million RMB, is expected
2015 China wearable devices
Market size will exceed 10 billion
To 11.49 billion RMB
Health-themed wearable devices
has recently been gradually increasing,
wearable device products some can collect information including: blood pressure, heart rate and other signs of information, also use "chronobiology" analysis method, based on the physical condition, proposed detailed, personalized medical programs.
1. 2013, the Mindray takeover of U.S. ultra
Sound giant ZONARE, Fosun Pharmaceutical close purchased Israeli company Alma to enter the medical
Weichuang medical acquired U.S.
Wright Medical orthopedic operations.
2. local companies expand overseas mergers and acquisitions and expand business scope abroad.
"Long-term Scientific and Technological Development Rules (2006-2020)", "the State Council on accelerating the cultivation and development of strategic emerging industries" are included in the key biological detection technologies and strategic industry development in September 2010.
Preventive, Predictive, Personalized, Participatory (4P) medical approach will replace traditional therapy-lead diagnosed approach
In 2010, the global IVD market size exceeded USD$40 billion, China IVD market approximated
RMB$15 billion (USD$ 250 million). In 2014, the global IVD market size has projected up to USD$50 billion, China IVD market could grow to RMB$25 billion.
IVD consumption per capita is only USD$1.5 in China, while in developed countries reached USD$25-30.
Source: McEvoy & Farmer,2010
Source：McEvoy & Farmer《China’s IVD Market(2011) 》
Global Molecular Diagnostics product
Sales & Sales (%)
The global molecular diagnostic market grows rapidly, which accounted for 2% in 1995 of IVD market share, up to 10 percent in 2009, its growth has exceeded 10% per annum, of which the China’s market has reached 20%+.
Molecular diagnostic products are used in the diagnosis of clinical subjects, such as cancer, infection, genetic and other applications proportion of 74% is applied to all other medical, technical services, third-party testing and rapid detection of microorganisms and other markets.
Increase in Total Size
Increase in Concentration
We are a healthcare firm that, while listed in Taiwan, is firmly rooted in China. We have a deep understanding of the healthcare market and we excel in the areas of product development and brand marketing.
Our superior performance is led by an industry-leading MNC-experienced, senior management team. We recruit only the best local talent.
Coland uses its market insights to choose specialty products in targeted markets, effectively launching them with our outstanding partners via our integrated commercialization platform.
To introduce superior pharmaceutical products, medical devices, and IVD reagents into the market.
To be the catalyst that enables our partners and their products to fully realize their potential.
To create value for our employees and shareholders through continuous growth.
We have strengthened our market presence and increasedour product offering through product in-licensing, co-development, strategic investment, JV, and M&A
*Generic name : Ursodeoxycholicacid
To build the most valuable healthcare commercialization platform, maximizing its value to human beings and shareholders now and in the future.
Rooted in China, Expanding to Asia, possessing a global view
COLAND GROUPTaipei Office
ADD：1st Floor, No. 866, Halei Rd, ZhangjiangHightech Park, ADD：Rm. D, 10F., No.170, Dunhua N. Rd., Songshan Dist., Shanghai, China Taipei City 105, TaiwanWEB：www.colandpharma.com